title: Incomplete vitreomacular traction release using intravitreal ocriplasmin.
abstract: OBJECTIVE
  To report the clinical course of our first 7 consecutive patients treated with intravitreal ocriplasmin (Jetrea(®)).
  
  
  METHODS
  Retrospective case series of the first 7 patients treated with ocriplasmin between January and December 2013 at an academic tertiary care center.
  
  
  RESULTS
  The average age was 78.4 years (range: 63-92). Five patients were pseudophakic and 2 patients were phakic in the injected eye. The median baseline visual acuity (VA) was 20/60 (range: 20/25 to 20/200). The median 1-month postinjection VA was 20/70, with a mean loss of 2 lines of VA among all patients. None of the patients had complete resolution of their vitreomacular traction or macular hole at 1 month of follow-up. Three patients had subsequent pars plana vitrectomy and membrane peeling surgery. The mean follow-up period for those who did not undergo vitrectomy was 9 months (range: 1-13). One patient with known ocular hypertension had an increase in intraocular pressure requiring topical pressure-lowering eyedrops. There were no cases of postinjection uveitis, endophthalmitis, retinal tears, or retinal detachment.
  
  
  CONCLUSIONS
  While ocriplasmin may be a viable pharmacological agent for vitreolysis, we present a series of patients that all had incomplete resolution of vitreomacular traction with and without full-thickness macular hole. There was an associated reduction in VA after ocriplasmin treatment at 1 month of follow-up. Careful analysis of the vitreoretinal interface and comorbid eye conditions is required to optimize outcome success with ocriplasmin.
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: Eric K
authors.initials: EK
authors.lastname: Chin
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: David R P
authors.initials: DR
authors.lastname: Almeida
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: Elliott H
authors.initials: EH
authors.lastname: Sohn
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: H Culver
authors.initials: HC
authors.lastname: Boldt
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: Vinit B
authors.initials: VB
authors.lastname: Mahajan
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: Karen M
authors.initials: KM
authors.lastname: Gehrs
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Russell
authors.affiliation: Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
authors.forename: James C
authors.initials: JC
authors.lastname: Folk
keywords: Jetrea®; Macular hole; Ocriplasmin; Vitrectomy; Vitreolysis; Vitreomacular adhesion; Vitreomacular traction